Skip to main content
Premium Trial:

Request an Annual Quote

Leica, Flagship Ink CDx Deal

NEW YORK (GenomeWeb) – Danaher's Leica Biosystems will use Flagship Biosciences' custom algorithms to develop companion diagnostics on the Aperio ePathology imaging platform, Flagship said today.

Financial and other terms of the deal were not disclosed.

"It is critical for our pharmaceutical customers' quantitative algorithms to have access to a platform with the largest installed base in the market," Flagship CEO Steven Potts said in a statement. "Knowing that the quantitative pathology approaches can be delivered on the Leica systems helps to mitigate risk and difficulties in transitioning a companion diagnostic to clinical usage."

Based in Boulder, Colo., Flagship provides quantitative histopathology services for pharma and device development and develops tissue-based companion diagnostics.